2020 Insights into the Weight Loss & Weight Management Industry

Dublin, April 06, 2020 (GLOBE NEWSWIRE) -- The "Weight Loss/Weight Management (Obesity) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Weight Loss/Weight Management (Obesity) market. A detailed picture of the Weight Loss/Weight Management (Obesity) pipeline landscape is provided, which includes the disease overview and treatment guidelines.

The assessment part of the report embraces in-depth Weight Loss/Weight Management (Obesity) commercial assessment and clinical assessment of the Weight Loss/Weight Management (Obesity) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Weight Loss/Weight Management (Obesity) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of Weight Loss/Weight Management (Obesity) with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Weight Loss/Weight Management (Obesity) treatment.
• Weight Loss/Weight Management (Obesity) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Weight Loss/Weight Management (Obesity) market.

Key Questions Answered

• What are the current options for Weight Loss/Weight Management (Obesity) treatment?
• How many companies are developing therapies for the treatment of Weight Loss/Weight Management (Obesity)?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for the treatment of Weight Loss/Weight Management (Obesity)?
• How many Weight Loss/Weight Management (Obesity) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Weight Loss/Weight Management (Obesity)?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Weight Loss/Weight Management (Obesity) market?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Weight Loss/Weight Management (Obesity)?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Weight Loss/Weight Management (Obesity) therapies?
• What are the clinical studies going on for Weight Loss/Weight Management (Obesity) and their status?
• What are the results of the clinical studies and their safety and efficacy?
• What are the key designations that have been granted for the emerging therapies for Weight Loss/Weight Management (Obesity)?
• How many patents are granted and pending for the emerging therapies for the treatment of Weight Loss/Weight Management (Obesity)?

In-depth Weight Loss/Weight Management (Obesity) Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Weight Loss/Weight Management (Obesity) Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Weight Loss/Weight Management (Obesity) .
• In the coming years, the Weight Loss/Weight Management (Obesity) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Weight Loss/Weight Management (Obesity) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Weight Loss/Weight Management (Obesity) treatment market. Several potential therapies for Weight Loss/Weight Management (Obesity) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Weight Loss/Weight Management (Obesity) market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Weight Loss/Weight Management (Obesity) ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
  

Key Topics Covered:

1. Report Introduction

2. Weight Loss/Weight Management (Obesity)
2.1. Overview
2.2. History
2.3. Weight Loss/Weight Management (Obesity) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Weight Loss/Weight Management (Obesity) Diagnosis
2.6.1. Diagnostic Guidelines

3. Weight Loss/Weight Management (Obesity) Current Treatment Patterns
3.1. Weight Loss/Weight Management (Obesity) Treatment Guidelines

4. Weight Loss/Weight Management (Obesity) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Weight Loss/Weight Management (Obesity) companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Weight Loss/Weight Management (Obesity) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Weight Loss/Weight Management (Obesity) Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Weight Loss/Weight Management (Obesity) Late Stage Products (Phase-III)

7. Weight Loss/Weight Management (Obesity) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Weight Loss/Weight Management (Obesity) Discontinued Products

13. Weight Loss/Weight Management (Obesity) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Weight Loss/Weight Management (Obesity) Key Companies

15. Weight Loss/Weight Management (Obesity) Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Weight Loss/Weight Management (Obesity) Unmet Needs

18. Weight Loss/Weight Management (Obesity) Future Perspectives

19. Weight Loss/Weight Management (Obesity) Analyst Review

20. Appendix

21. Report Methodology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hwb1s5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900